Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers

10.1097/FTD.0000000000000298

Saved in:
Bibliographic Details
Main Authors: Lee, JW, Pussegoda, K, Rassekh, SR, Monzon, JG, Liu, G, Hwang, S, Bhavsar, AP, Pritchard, S, Ross, CJ, Amstutz, U, Carleton, BC, Hayden, MR, MacLeod, S, Smith, A, Brunham, L, Aminkeng, F, Shear, NH, Koren, G, Ito, S, Madadi, P, Rieder, MJ, Kim, R, Maher, M, Flockhart, D
Other Authors: COMMUNITY,OCCUPATIONAL & FAMILY MEDICINE
Format: Review
Published: Ovid Technologies (Wolters Kluwer Health) 2022
Subjects:
Antineoplastic Agents
Cisplatin
Genetic Markers
Hearing Loss
Humans
Pharmacogenetics
Polymorphism, Genetic
Online Access:https://scholarbank.nus.edu.sg/handle/10635/235097
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore

Similar Items

Similar Items